Viatris Inc. stock rises 1.01% to $14.97, outperforming market decline

8 articles · Updated · MarketWatch · Apr 29

On Wednesday, Viatris Inc. shares closed at $14.97, marking their third consecutive day of gains despite the S&P 500 and Dow Jones both falling.
The stock remains 9.11% below its 52-week high of $16.47 set on February 26th, with trading volume reaching 12.1 million, surpassing its 50-day average.
Viatris Inc.'s performance stands out amid a broadly negative session for major indices, reflecting investor confidence as the company continues to recover from earlier market pressures.

Ahead of its May 7 earnings report, what is the biggest threat to Viatris's recent stock rally?

Will FDA approval for its eye drop Ryzumvi® finally push Viatris past its 52-week high?

With $11 billion to deploy by 2030, what strategic acquisitions might Viatris target next?

Is Viatris a true turnaround story or a value trap with hidden operational risks?

Viatris is cutting 10% of its workforce. Can it hit ambitious growth targets with a leaner team?

How will the BIOSECURE Act reshape Viatris's global manufacturing strategy and its reliance on foreign suppliers?